Peginterferon alfa-2a in patients with chronic hepatitis C.

By Stefan Zeuzem, S. Feinman, J. Rasenack, E. Heathcote, Ming-Yang Lai, Edward J. Gane, J. O'Grady, J. Reichen, Moisés Diago, A. Lin and 2 more. New England Journal of Medicine, 2000

1,213 citations recorded by the source corpus.

Subfields: Hepatology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/3ddc9f4d64ffceb0fdd6e658bb8ac43c0166e5cc

Citations in the corpus

• Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. (2000, neutral): “7,8 9-11 Recent data 12 suggest that the sustained virologic response achieved with peginterferon alfa-2a is similar to that observed for interferon alfa-2a in combination with ribavirin in patients with hepatitis C. 13 In addition, the tolerability of peginterferon is similar to that of the…”
• Effect of pegylation on pharmaceuticals (2003, neutral): “The investigators concluded that “a regimen of peginterferon α2a given once weekly is more effective than a regimen of interferon α2a given three times weekly&rdquo”